PolyPeptide Group
/ Key word(s): AGMEGM
Media release PolyPeptide publishes invitation to the annual General Meeting 2025 Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug. At PolyPeptide Group AG’s (the “Company”) fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug (the “AGM 2025”), five current members of the Board of Directors will stand for re-election. Beat In-Albon has decided not to stand for re-election as a member of the Board of Directors. The Board of Directors thanks Mr. In-Albon for his dedicated service and valuable contributions. Peter Wilden is proposed for re-election as Chair of the Board of Directors, and Philippe Weber and Peter Wilden as members of the Remuneration and Nomination Committee. As announced on 11 March 2025, the Board of Directors further proposes Jo LeCouilliard for election as new independent member of the Board of Directors, and upon election it is expected that Ms. LeCouilliard will join the Audit and Risk Committee. The Board of Directors further proposes to the AGM 2025 the introduction of a capital band in a new art. 3a of the Company's Articles of Association and the introduction of a conditional share capital for financing purposes and finance instruments in a new art. 3c of the Company's Articles of Association. The capital band shall provide the Board of Directors with the flexibility to increase the Company’s share capital within a predefined range, thereby enhancing the Company's financial and strategic agility. The conditional share capital shall increase the Company's financing and refinancing flexibility. Further proposals include, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders will also be asked to approve the Management Report, Statutory Financial Statements, Consolidated Financial Statements and the report on non-financial matters, in each case, for the financial year 2024 as well as the Remuneration Report 2024 in separate consultative vote. The invitation to the AGM 2025 with the detailed proposals and explanations can be found on the Company’s . Contact PolyPeptide Group AG Michael Stäheli Head of Investor Relations & Corporate Communications T: About PolyPeptide PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit . @PolyPeptide – follow us on Disclaimer This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.
End of Media Release |
Language: | English |
Company: | PolyPeptide Group |
Neuhofstrasse 24 | |
6340 Baar | |
Switzerland | |
Phone: | |
E-mail: | |
Internet: | |
ISIN: | CH1110760852 |
Valor: | 111076085 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2101938 |
End of News | EQS News Service |
|
2101938 18.03.2025 CET/CEST